IndustriesPharma and Life Sciences

PHARMA AND LIFE SCIENCES

Finding knowledge should not take longer than using it.

We organize research, scientific documentation, and knowledge management across distributed sources. Architecture follows data privacy and information sensitivity.

Assess a process See the process
SourcesSearchClassificationReviewKnowledge

A conceptual flow. Each organization defines sources, permissions, and restrictions.

SECTOR PROCESS

Documentation crosses more than one system and more than one review.

We address information processes. We do not attribute undocumented regulatory, clinical, or pharmaceutical projects.

  1. 01

    Search

    Locate relevant material across authorized repositories and scientific sources.

  2. 02

    R&D / research

    Gather background and prepare scientific knowledge for analysis.

  3. 03

    Classification

    Organize technical documentation by criteria the team can review.

  4. 04

    Document processing

    Identify fields, concepts, or references in large volumes.

  5. 05

    Review and validation

    Present evidence and context to the person responsible for quality.

  6. 06

    Document control

    Preserve outcomes, traceability, sources, and versions for later use.

KNOWLEDGE FRICTIONS

The information exists. Finding and preparing it occupies the team.

  • Search is repeated across internal systems and scientific sources.
  • Scientific knowledge is distributed across documents and people.
  • Classifying regulatory documentation takes time before analysis can begin.
  • Intellectual property and sensitive information limit tools and providers.
  • Review starts without a shared view of sources and versions.
  • Regulated information loses value when traceability is not retained.

NEED → INTERVENTION

Not every search needs an agent. Not every document needs AI.

The combination depends on volume, information type, and architectural constraints.

Separate sources and repositoriesSystems integration

Repeated classificationProcess automation

Text requiring interpretationAI consulting

Multi-stage researchSupervised AI agents

SOURCES AND KNOWLEDGE

Architecture starts with the constraint.

We assess data privacy, information security, intellectual property, data residency, and access before choosing services or models.

Document repositories

Technical files, versions, and internal knowledge.

Databases and search

Structured or indexed sources available for consultation.

Internal applications

Proprietary workflows, reviews, and tools.

Authorized services

External providers only when restrictions allow them.

SENSITIVE INFORMATION + KNOWLEDGE

External, local, or hybrid. There is no universal answer.

The decision combines sensitivity, integration, operations, performance, and control.

01

External service

May be assessed when privacy, policy, and data residency allow processing outside the environment.

02

Private / local AI

A local or on-premise AI model keeps processing within controlled architecture.

03

Hybrid architecture

Separates tasks and data so each environment operates within defined boundaries.

We do not recommend an architecture by default. We first understand information, constraints, and operations.

CAPABILITIES IN CONTEXT

Technology that reduces work around knowledge.

01

Connect authorized sources

We connect repositories and applications without erasing their responsibilities.

Explore integration
02

Prepare documentation

We automate classification, movement, notifications, and repeatable steps.

Explore automation
03

Research with control

We assess AI and agents with defined sources, permissions, and review.

Explore AI agents

GENERAL EVIDENCE · R&D

Research with local processing.

>75%

Reduction in research time using a fully local, closed model without sending sensitive information to external cloud services.

This is general R&D evidence. It is not a confirmed Pharma case and is not attributed to a pharmaceutical client.

CLEAR BOUNDARIES

Understanding the problem without inventing credentials.

  • We do not claim GMP, FDA, ANMAT, clinical-trial, or pharmacovigilance experience.
  • We do not present the R&D case as a Pharma case.
  • We do not recommend cloud, local, or hybrid without assessing constraints.
  • We do not promise to replace scientific or human review.

NEXT STEP

Where does information work slow down today?

Tell us which research, documentation, or knowledge process consumes team capacity.

Assess a process